These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

78 related items for PubMed ID: 12497074

  • 1. Investigating the clinical utility of the percent of positive prostate biopsies in predicting PSA outcome following local therapy for patients with clinically localized prostate cancer.
    D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Silver B, Henry L, Hurwitz M, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Richie JP.
    Prostate Cancer Prostatic Dis; 2000 Dec; 3(4):259-264. PubMed ID: 12497074
    [Abstract] [Full Text] [Related]

  • 2. Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer.
    D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Silver B, Henry L, Hurwitz M, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Richie JP.
    Mol Urol; 2000 Dec; 4(3):171-5;discussion 177. PubMed ID: 11062371
    [Abstract] [Full Text] [Related]

  • 3. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
    Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC, SEARCH Database Study Group.
    J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
    [Abstract] [Full Text] [Related]

  • 4. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C, Kestin LL, Weed DW, Krauss D, Vicini FA, Martinez AA.
    Int J Radiat Oncol Biol Phys; 2005 Mar 01; 61(3):714-24. PubMed ID: 15708249
    [Abstract] [Full Text] [Related]

  • 5. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC.
    Cancer; 2003 Dec 01; 98(11):2344-50. PubMed ID: 14635068
    [Abstract] [Full Text] [Related]

  • 6. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW, Schild SE, Vora SA, Halyard MY.
    Int J Radiat Oncol Biol Phys; 2004 Sep 01; 60(1):24-9. PubMed ID: 15337536
    [Abstract] [Full Text] [Related]

  • 7. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):795-9. PubMed ID: 15925452
    [Abstract] [Full Text] [Related]

  • 8. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer.
    D'Amico AV, Schultz D, Silver B, Henry L, Hurwitz M, Kaplan I, Beard CJ, Renshaw AA.
    Int J Radiat Oncol Biol Phys; 2001 Mar 01; 49(3):679-84. PubMed ID: 11172949
    [Abstract] [Full Text] [Related]

  • 9. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.
    Yokomizo A, Murai M, Baba S, Ogawa O, Tsukamoto T, Niwakawa M, Tobisu K, Kinukawa N, Naito S.
    BJU Int; 2006 Sep 01; 98(3):549-53. PubMed ID: 16925752
    [Abstract] [Full Text] [Related]

  • 10. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
    Freedland SJ, Presti JC, Terris MK, Kane CJ, Aronson WJ, Dorey F, Amling CL, SEARCH Database Study Group.
    J Urol; 2003 Jun 01; 169(6):2129-35. PubMed ID: 12771734
    [Abstract] [Full Text] [Related]

  • 11. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
    Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV.
    J Clin Oncol; 2005 Oct 01; 23(28):6992-8. PubMed ID: 16192586
    [Abstract] [Full Text] [Related]

  • 12. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy.
    Miyake H, Kurahashi T, Hara I, Takenaka A, Fujisawa M.
    BJU Int; 2007 Feb 01; 99(2):315-20. PubMed ID: 17155986
    [Abstract] [Full Text] [Related]

  • 13. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy.
    Kamat AM, Babaian K, Cheung MR, Naya Y, Huang SH, Kuban D, Babaian RJ.
    J Urol; 2003 Nov 01; 170(5):1860-3. PubMed ID: 14532793
    [Abstract] [Full Text] [Related]

  • 14. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer.
    D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Fondurulia J, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP.
    J Clin Oncol; 2000 Mar 01; 18(6):1164-72. PubMed ID: 10715284
    [Abstract] [Full Text] [Related]

  • 15. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA, Halvorsen OJ, Daehlin L, Hostmark J, Akslen LA.
    BJU Int; 2006 Jan 01; 97(1):51-5. PubMed ID: 16336328
    [Abstract] [Full Text] [Related]

  • 16. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients.
    King CR, McNeal JE, Gill H, Presti JC.
    Int J Radiat Oncol Biol Phys; 2004 Jun 01; 59(2):386-91. PubMed ID: 15145152
    [Abstract] [Full Text] [Related]

  • 17. Is there a difference in outcome after radical prostatectomy between patients with biopsy Gleason sums 4, 5, and 6? Results from the SEARCH database.
    Freedland SJ, Amling CL, Terris MK, Presti JC, Aronson WJ, Elashoff D, Kane CJ, SEARCH Database Study Group.
    Prostate Cancer Prostatic Dis; 2003 Jun 01; 6(3):261-5. PubMed ID: 12970733
    [Abstract] [Full Text] [Related]

  • 18. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
    Shariat SF, Abdel-Aziz KF, Roehrborn CG, Lotan Y.
    Eur Urol; 2006 Feb 01; 49(2):293-302. PubMed ID: 16387412
    [Abstract] [Full Text] [Related]

  • 19. Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen.
    San Francisco IF, Regan MM, Olumi AF, DeWolf WC.
    J Urol; 2004 Apr 01; 171(4):1492-9. PubMed ID: 15017206
    [Abstract] [Full Text] [Related]

  • 20. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
    Villamón-Fort R, Martínez-Jabaloyas JM, Soriano-Sarriá P, Ramos-Soler D, Pastor-Hernández F, Gil-Salom M.
    Urol Int; 2007 Apr 01; 78(4):328-33. PubMed ID: 17495491
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.